rawfin.tv
Eli Lilly Shares Decline on Weak Obesity Drug Data
MarketsstocksAI Generated

Eli Lilly Shares Decline on Weak Obesity Drug Data

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Eli Lilly's stock fell after reporting weaker-than-expected obesity drug prescription data. The development suggests Novo Nordisk's Wegovy is extending its lead in the competitive weight-loss medication market.

Eli LillyNovo NordiskPharmaceuticalsWeight-Loss Drugs

Related Articles

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks
Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

stocks